Vertex pauses diabetes islet cell therapy study after two patient deaths it says are unrelated to drug
Vertex has paused the Phase I/II study of its islet cell therapy for type 1 diabetes following the death of two patients, though the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
